Can you help advance cell therapy and regenerative medicine programs?
If so, we have an audience of stem cell entrepreneurs, innovators and disruptors looking to move their business forward.
'Very well organised conference with excellent networking facilities'
Nico Verlinden, Perkin Elmer
‘Good exhibition area, good traffic’
Rudolf Schmitt, GE Healthcare Europe
‘Interesting talks and high level discussions with good networking’
Markus Sack, RWTH Aachen University
The Pharmaceutical and Biotechnology continue to dominate the world’s R&D expenditure, with more companies in the top 10 than any other sector. This year, whilst Novartis has knocked Roche from their top spot, individual R&D spends by pharma and biotechs fail to compete with the likes of Volkswagen and Samsung who’s spends were around $11 […]
Earlier this year at BioPharma Asia Convention, when we spoke to some speakers about their thoughts on the key growth strategy that Asian biotech companies should adopt, there seemed to be a unanimous agreement that looking beyond Asia is the way to go. “Biotech companies in Asia have to think globally, and link globally. “ […]
Antibody therapies have grown up – gone are the days of monoclonal antibody therapies (mAbs) being the sole proprietor of a good biologics approach to tackling a disease. Today, antibody therapies range from fusion proteins (such as the ever popular Antibody-Drug Conjugates, ADCs), radio-labeled antibodies, bi-specifics and numerous other novel niceties conjured up by our […]
Innovation and strategy for pharmaceutical, biotech and R&D